COMPLE X TRE ATMENT OF OSTEOPOROSIS IN PATIENTS WITH 2 T YPE DIABETES MELLITUS IN COMBINATION WITH NON-ALCOHOLIC FATTY LIVER DISEASE

Authors

  • Titova Ju. A. SI «V. Danilevsky Institute of Endocrine Pathology Problems of NAMS of Ukraine», Kharkiv, Ukraine

DOI:

https://doi.org/10.21856/j-PEP.2019.1.07

Keywords:

type 2 diabetes mellitus, osteoporosis, non-alcoholic fatty liver disease, calcium, magnesium, vitamin D

Abstract

An actual problem of modernity is the relationship between type 2 diabetes mellitus (DM) and osteoporosis
(OP), as well as type 2 DM with non-alcoholic fatty liver disease (NAFLD), which are actively considered by scientists.
There are different data on the development and course of OP, depending on gender, age and race. So the
aim of the study was to determine the tactics of treatment of OP in patients with type 2 DM with NAFLD. 37
patients with type 2 DM with OP and NAFLD (15 men and 22 women) were examined and treated. When examining
patients with type 2 DM with OP and NAFLD before treatment, there was a deficiency of vitamin D, that
is, none of the patients had an adequate supply of vitamin D, while the indicators of the level of CA were in the
normal range, and the indicators of Ca++ were reduced, so they were prescribed therapy with magnesium, vitamin
D, calcium in daily doses, depending on gender, age, revealed pathology and laboratory abnormalities, and
all patients received individually selected therapy with sugar-lowering. To assess the degree of compensation
of carbohydrate metabolism was carried out to study the level of glycosylated hemoglobin (HbA1c) and further
correction zakreslajac therapy. According to the results of the study, the expediency of prescribing drugs that affect
the improvement of bone structure in patients with type 2 DM with OP in daily doses depending on gender,
age, degree of detected violations and deviations of laboratory parameters was proved, and it was determined
that the improvement of bone tissue has a positive effect on the compensation of carbohydrate metabolism in the
examined patients. It was found that patients with type 2 DM with OP and NAFLD require monitoring with
densitometry and laboratory diagnosis in dynamics against the background of treatment.

References

International Diabetes Federation. Diabetes Atlas. 8th ed 2017: 150 p.

Johnell O. Osteoporosis Int 2004; 15 (11): 897-902.

Vertkin AL, Naumov AV. Osteoporoz, Moskva, 2015: 256 p.

Lesnyak OM, Benevolenskaya LI. Osteoporoz, 2nd ed, Moskva, 2012: 272 p.

Dedov II, Mel'nichenko GA, Belaja ZhJe, et al. Problemy Jendokrinologii 2011; 1: 35-45.

Izaolaa M, Escuderoe E, Herrerose V. Ann Nutr Metab 2004; 48: 141-145.

Shanbhogue VV, Hansen S, Frost M, et al. Lancet Diabetes Endocrinol 2017; 5 (10): 827-838. doi: http://doi.org/10.1016/S2213-8587(17)30134-1.

Fassio A, Idolazzi L, Rossini M, et al. Eat Weight Disord 2018; 23 (3): 293-302. doi: http://doi.org/10.1007/s40519-018-0505-2.

Walsh JS, Vilaca T. Calcif Tissue Int 2017; 100 (5): 528-535. doi: http://doi.org/10.1007/s00223-016-0229-0.

Oz S, Guven G, A. Kilicarslan, et al. J Natl Med Assoc 2006; 10: 1598-1604. doi: http://doi.org/10.4314/ahs.v15i3.25.

Majima T, Komatsu Y, Yamada T, et al. Osteoporos Int 2005; 168: 907-913. doi: http://doi.org/10.1007/s00198-004-1786-z.

Yamagishi S, Nakamura K, Inoue H. Med Hypotheses 2005; 6: 1013-1015. doi: http://doi.org/10.1016/j.mehy.2005.07.017.

Alikhani M, Alikhani Z, Boyd C, et al. Bone 2007; 2:345-353. doi: http://doi.org/10.1016/j.bone.2006.09.011.

Rubin MR. Ann N Y Acad Sci 2017; 1402 (1): 18-30. doi: http://doi.org/10.1111/nyas.13463.

Adil C, Aydın T, Taşpınar Ö, et al. J Phys Ther Sci 2015; 27 (1): 179-182. doi: http://doi.org/10.1589/jpts.27.179.

Manolagas SC. Endocr Rev 2000; 21: 115-137. doi: http://doi.org/10.1210/edrv.21.2.0395.

Akkawi I, Zmerly H. Joints 2018; 6 (2): 122-127. doi:http://doi.org/10.1055/s-0038-1660790.

Christakos S, Veldurthy V, Patel N, Wei R.Adv Exp Med Biol 2017;1033: 3-12.doi: http://doi.org/10.1007/978-3-319-66653-2_1.

Ahlstrom M, Flynn A. Proc Nutr Soc 2003; 62: 851-858.

Mankovic V. Int J Med 1992; 231: 151-160.

Martynov AI, Urlaeva IV, Akatova EV. Consilium Medicum 2014; 16 (1): 43-46.

Ivashkin VT, Lapina TL. Gastrojenterologija: nacional'noe rukovodstvo, Moskva, 2013: 704 p.

Kiseleva IV. Sovremen problemy nauki i obrazovanija 2014; 3: 553.

Kozlovskij AA. Klin praktika i zdorov'e 2013; 2/2: 21-36.

Syniachenko OV, Yermolaeva MV, Heiko IA, et al. Trauma 2013; 14 (1): 57-64.

Vvedenskiy BP, Kovalev GA, Dedukh NV, Sandomirskiy BP. Problems of Cryobiology and cryomedicine 2016;26 (4): 15-28.

Golovach IJu. Travma 2013; 14(1): 57-64.

Martin TJ. J Bone Metab 2014; 21 (1): 8-20. doi: http://doi.org/10.11005/jbm.2014.21.1.8.

Zotkin EG, Shvarc OJa. Jeffektivnaja Farmakoterapija 2013;1: 50-59.

Gromova OA, Gupalo EM. Voprosy ginekologii, akusherstva i perinatologii 2008; 7 (4): 73-82.

Shupina MI, Nechaev GI. Poseshhenie Vracha 2014; 12:37-40.

Aspray TJ, Yan L, Prentice A. Bone 2005; 36: 710-720.doi: http://doi.org/10.1016/j.bone.2005.01.002.

Povoroznjuk VV, Orlyk VT, Perezevich IN. Bone 2008;42: 83-84.

Torgerson DJ, Bell-Syer SE. JAMA 2001; 285: 2891-2897.

Cranney A. BMJ 2003; 327: 355-356. doi: https://doi.org/10.1136/bmj.327.7411.355.

Downloads

Published

2021-07-06

How to Cite

Titova, J. A. . (2021). COMPLE X TRE ATMENT OF OSTEOPOROSIS IN PATIENTS WITH 2 T YPE DIABETES MELLITUS IN COMBINATION WITH NON-ALCOHOLIC FATTY LIVER DISEASE. Problems of Endocrine Pathology, 67(1), 60-68. https://doi.org/10.21856/j-PEP.2019.1.07

Issue

Section

CLINICAL ENDOCRINOLOGY